Navigation Links
2013 Paxil Birth Defect Allegation Cases Now Being Investigated by Resource4thePeople Attorneys

San Diego, CA (PRWEB) March 31, 2013

Resource4thePeople announced today that its lawyers are now investigating 2013 cases from families who are inquiring about whether alleged birth defects suffered by their infants may have been caused by the use of Paxil and other, similar, anti-depressants.

"Increasing numbers of consumers have been contacting us about their legal rights in connection with the use of Paxil and other anti-depressants known as serotonin reuptake inhibitors," said Resource4thePeople.

"Therefore, our lawyers are now aggressively investigating claims that are being made by families in which the use of Paxil and other SSRIs allegedly caused birth defects in children born to mothers who used these medications while pregnant."

Resource4thePeople said that the increase in inquiries has come, in part, because of new findings* showing that the use of Paxil may be putting pregnant mothers at higher risk of having an infant with birth defects.

Paxil is one of the best-selling of the most recent class of anti-depressants, known as SSRIs. The medications moderate chemical messengers in the brain by blocking the reabsorption of the neurotransmitter serotonin.

Other popular SSRI anti-depressants include Zoloft, Lexapro, Prozac and Celexa.

"This recent study by respected researchers showing that the use of Paxil and some other SSRI anti-depressants during pregnancy is associated with increased risks of miscarriage, birth defects, preterm birth, newborn behavioral syndrome, persistent pulmonary hypertension of the newborn and possible longer term neurobehavioral effects has caused families to contact us about their legal rights," said Resource4thePeople.

"In response to these contacts our lawyers are providing free consultations about the legal rights that these families may be eligible for in connection with compensation for pain and suffering, loss of wages, medical costs and other expenses attributed to factors that were not of their making."

Links between the use of anti-depressants such as Paxil and birth defects in mothers who used the medications while pregnant have been recognized by the Food and Drug Administration since 2005.**

Now, the latest medical research study about these side effects was recently published in the Human Reproduction Oxford Journal, January, 2013 edition,* which confirms fears of increased birth defect risks detailed in FDA health warning communications.

This finding comes directly from the article:

"Antidepressant use during pregnancy is associated with increased risks of miscarriage, birth defects, preterm birth, newborn behavioral syndrome, persistent pulmonary hypertension of the newborn and possible longer term neurobehavioral effects. There is no evidence of improved pregnancy outcomes with antidepressant use."

These findings came in response to the research's study question: "What is the current literature on the safety and efficacy of selective serotonin reuptake inhibitor (SSRI) use in infertile women?"

Resource4thePeople notes that these concerns about increased risk of birth defects as a result of Paxil use also have been echoed by the Mayo Clinic, which posted the following warning about Paxil use by pregnant women:***

"Antidepressants and pregnancy: Some antidepressants may harm your unborn child if you take them during pregnancy or while you're breast-feeding. Paxil in particular appears to increase the risk of birth defects, including heart and lung problems. If you're taking an antidepressant and you're considering getting pregnant, talk to your doctor or mental health provider about the possible dangers. Don't stop taking your medication without contacting your doctor first."

Resource4thePeople also notes that one of the most recent Paxil birth defects lawsuits making such allegations was filed late last year..****

In that case a family is attributing the death of their baby daughter to a birth defect in her heart that the couple claim was caused by the use of Paxil and other anti-depressants by the mother during her pregnancy to fight depression, according to the court documents in the case.

"One of the important pieces of information we think that users of Paxil and other antidepressants should be aware of is the fact that Paxil's manufacturer, giant pharmaceutical GlaxoSmithKline, agreed to pay $3 billion to the federal government to settle allegations over its marketing and sales of Paxil and other products," said Resource4thePeople.

Information about this settlement***** is included on the Resource4thePeople web site, reflecting the U.S. Justice Department's announcement of what it described as massive health care fraud:

"GSK agreed to plead guilty to a three-count criminal information, including two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration (FDA).

Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK’s U.S. president and board of directors.

"GSK will also pay $2 billion to resolve its civil liabilities with the federal government under the False Claims Act, as well as the states. The civil settlement resolves claims relating to Paxil, Wellbutrin and Avandia, as well as additional drugs, and also resolves pricing fraud allegations."

**** Case # 2:2012cv05962 U.S. District Court, Eastern District of Pennsylvania

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Paxil Birth Defect Claims Now Being Investigated by Resource4thePeople Attorneys
2. Depo-Provera Birth Control Might Raise Breast Cancer Risk
3. Wellesley study shows income inequality a key factor in high US teen births
4. Planning Pregnancy May Cut Birth Defects
5. U.S. Teen Births Hit Record Low
6. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
7. New global report says US lags behind 130 other nations in preterm birth rate
8. Pneumonia and preterm birth complications are the leading causes of childhood death
9. Babies susceptibility to colds linked to immune response at birth
10. Birth Control Pills, HRT Tied to Digestive Ills
11. Fewer Stillbirths Among Pregnant Women Vaccinated Against Flu
Post Your Comments:
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 15th by ... handling security in light of the recent terrorist attacks in Paris, other cities are ... an attack from reaching U.S. soil. Especially around special events that may be high-profile ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)...  ARKRAY USA , Inc., a ... demonstrating the accuracy of its blood glucose meter systems. ... Diabetes and Cardiovascular Disease in Los Angeles ... ® 01 meter and the Assure ® ... to accurately measure glucose levels in blood is essential ...
Breaking Medicine Technology: